<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445443</url>
  </required_header>
  <id_info>
    <org_study_id>13-4042-01</org_study_id>
    <nct_id>NCT02445443</nct_id>
  </id_info>
  <brief_title>LEGION Hinge Safety and Efficacy Study</brief_title>
  <acronym>LINKS</acronym>
  <official_title>A Prospective, Multi-center Clinical Study Evaluating the LEGION™ Hinge Knee System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current investigation is to assess the safety and efficacy of a new hinged&#xD;
      revision knee device. This device is designed to provide efficient, reproducible&#xD;
      reconstructions with optimal limb and implant alignment, durable implant fixation, and&#xD;
      functional outcomes that increasingly approach those of primary Total Knee Arthroplasty&#xD;
      (TKA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to demonstrate statistically significant improvements in the&#xD;
      original Knee Society Clinical Score (KSCS) from baseline to 1 and 2 years in subjects using&#xD;
      the LEGION™ Hinge Knee System. The focus of the 1 and 2 year analyses will be on safety and&#xD;
      efficacy. The 5 year analysis will focus on survivorship and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2015</start_date>
  <completion_date type="Anticipated">March 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Original Knee Society Clinical Score© (KSCS)</measure>
    <time_frame>1 year</time_frame>
    <description>The original Knee Society Score© (KSS) is subdivided into two parts. One part is the Knee Society Clinical Score (KSCS) and the other part is the Knee Society Functional Score (KSFS). The KSCS will be administered at the pre-operative visit and all follow-up visits. The purpose of administering this assessment is to determine the statistical clinical improvement over time which may be compared to literature at 1 and 2 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Revision</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Revision, for any reason, will be assessed throughout the subject's participation in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Original Knee Society Functional Score© (KSFS)</measure>
    <time_frame>1 year</time_frame>
    <description>The original Knee Society Score© (KSS) is subdivided into two parts. One part is the Knee Society Clinical Score (KSCS) and the other part is the Knee Society Functional Score (KSFS). The purpose of administering this assessment is to determine the statistical clinical improvement over time which may be compared to literature at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Original Knee Society Functional Score© (KSFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The original Knee Society Score© (KSS) is subdivided into two parts. One part is the Knee Society Clinical Score (KSCS) and the other part is the Knee Society Functional Score (KSFS). The purpose of administering this assessment is to determine the statistical clinical improvement over time which may be compared to literature at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2011 Knee Society Score©</measure>
    <time_frame>1 year</time_frame>
    <description>2011 Knee Society Knee Score and all of it's components</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2011 Knee Society Score©</measure>
    <time_frame>2 years</time_frame>
    <description>2011 Knee Society Knee Score and all of it's components</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-3L™</measure>
    <time_frame>1 year</time_frame>
    <description>The EuroQol EQ-5D-3L™ is a descriptive system measuring health-related Quality Of Life (QOL) and consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which takes one of three responses. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D-3L™ dimension. The EQ-5D-3L™ is completed by the Subject on the day of their visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-3L™</measure>
    <time_frame>2 years</time_frame>
    <description>The EuroQol EQ-5D-3L™ is a descriptive system measuring health-related Quality Of Life (QOL) and consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which takes one of three responses. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D-3L™ dimension. The EQ-5D-3L™ is completed by the Subject on the day of their visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Original Knee Society Clinical Score© (KSCS)</measure>
    <time_frame>2 Years</time_frame>
    <description>The original Knee Society Score© (KSS) is subdivided into two parts. One part is the Knee Society Clinical Score (KSCS) and the other part is the Knee Society Functional Score (KSFS). The KSCS will be administered at the pre-operative visit and all follow-up visits. The purpose of administering this assessment is to determine the statistical clinical improvement over time which may be compared to literature at 1 and 2 years.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Knee Arthroplasty, Total</condition>
  <arm_group>
    <arm_group_label>LEGION Hinge Knee System</arm_group_label>
    <description>This group will be receiving the LEGION Hinge device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LEGION Hinge Knee System</intervention_name>
    <description>All enrolled/treated subjects will receive the LEGION Hinge Knee System.</description>
    <arm_group_label>LEGION Hinge Knee System</arm_group_label>
    <other_name>LEGION HK</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring a revision total knee arthroplasty (TKA) using the LEGION Hinge Total&#xD;
        Knee system.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has gross knee instability resulting from loss of collateral ligament&#xD;
             function, gross bone loss, comminuted fractures of the proximal tibia or distal femur,&#xD;
             rheumatoid arthritis, post-traumatic arthritis, osteoarthritis, degenerative&#xD;
             arthritis, failed osteotomies, unicompartmental replacement or total knee replacement,&#xD;
             or absent or incompetent posterior cruciate ligament and one or both of the collateral&#xD;
             ligaments&#xD;
&#xD;
          -  Subject has a failed primary or revision knee replacement&#xD;
&#xD;
          -  Subject is 18-80 years of age&#xD;
&#xD;
          -  Subject is skeletally mature in Investigator's judgment i.e., subject is not actively&#xD;
             growing or does not have immature bones for any reason&#xD;
&#xD;
          -  Subject has met an acceptable preoperative medical clearance and is free of or treated&#xD;
             for cardiac, pulmonary, hematological, infection or other conditions that would pose&#xD;
             excessive operative risk&#xD;
&#xD;
          -  Subject is willing to sign and date an IRB/EC-approved consent form&#xD;
&#xD;
          -  Subject plans to be available through the five (5) year postoperative follow-up&#xD;
&#xD;
          -  If of child bearing potential, Subject reports she is not pregnant nor plans to become&#xD;
             pregnant during the study&#xD;
&#xD;
          -  Subject agrees to follow the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is receiving the study device as a primary knee replacement&#xD;
&#xD;
          -  Subject has presence of malignant tumor, metastatic, or neoplastic disease&#xD;
&#xD;
          -  Subject is not expected to return to normal ambulatory function (i.e., morbid obesity&#xD;
             or other limiting co-morbidities)&#xD;
&#xD;
          -  Subject is pregnant or plans to become pregnant during the course of the study&#xD;
&#xD;
          -  Subject has conditions that may interfere with the revision arthroplasty survival or&#xD;
             outcome (i.e., Paget's or Charcot-Marie-Tooth disease, vascular insufficiency,&#xD;
             muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or&#xD;
             neuromuscular disease)&#xD;
&#xD;
          -  Subject has known (Subject reported) metal hypersensitivity&#xD;
&#xD;
          -  Subject has an emotional or neurological condition that would pre-empt their ability&#xD;
             or willingness to participate in this study&#xD;
&#xD;
          -  Subject has BMI&gt;45&#xD;
&#xD;
          -  Subject is participating in any other pharmaceutical, biologic, or medical device&#xD;
             clinical investigation or has been treated with an investigational product in the past&#xD;
             30 days&#xD;
&#xD;
          -  Subject is facing current or impending incarceration&#xD;
&#xD;
          -  Subject is not a good candidate for the study based on Investigator opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachael Winter</last_name>
    <role>Study Director</role>
    <affiliation>Smith &amp; Nephew, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maya Simons</last_name>
    <phone>8482700187</phone>
    <email>maya.simons@smith-nephew.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Hospital for Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Aponte</last_name>
      <phone>212-460-0176</phone>
      <email>Ariel.Aponte@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Ivelisse Rodriguez Pagan</last_name>
      <phone>212-598-2311</phone>
      <email>Ivelisse.pagan@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ran Schwarzkopf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Marwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Slover, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Vigdorchik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erh-ting Hsu</last_name>
      <email>hsuer@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Huff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute at Baylor Regional Medical Center Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Fremantle Hospital</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Searle</last_name>
      <phone>(08) 9431 3867</phone>
      <email>mary.searle@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Carole Steggall</last_name>
      <phone>(08) 9431 3867</phone>
      <email>carole.steggall@health.wa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Piers Yates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gareth Prosser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopaedics WA St John of God Hospital Murdoch</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven campus Pellenberg</name>
      <address>
        <city>Pellenberg</city>
        <zip>3212</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristel Van de loock</last_name>
      <phone>016 34 12 66</phone>
      <email>kristel.vandeloock@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Rowie de Buysscher</last_name>
      <phone>+32 16 33 88 18</phone>
      <email>Rowie.debuysscher@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Hilde Vandenneucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Luyckx, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concordia Hip and Knee Institute</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2K 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Tran</last_name>
      <phone>+1 204 926 1231</phone>
      <email>stran@orthoinno.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Turgeon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Bohm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin Burnell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Hedden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Olivia Pérez</last_name>
      <email>loliva@mutuaterrassa.cat</email>
    </contact>
    <investigator>
      <last_name>Daniel Haro Fernández, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

